Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Published: Thursday 12th December 2024
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in:

Open Access 01-12-2024 | Cancer Therapy | Review

Towards precision medicine: design considerations for nanozymes in tumor treatment

Authors: Xinqiao Li, Jinpeng Hu, Qi Zhao, Weifeng Yao, Zhitao Jing, Zhizhong Jin

Published in: Journal of Translational Medicine | Issue 1/2024

Login to get access

Abstract

Since the discovery of Fe3O4 nanoparticles with enzyme-like activity in 2007, nanozymes have emerged as a promising class of catalysts, offering advantages such as high catalytic efficiency, low cost, mild reaction conditions, and excellent stability. These properties make nanozymes highly suitable for large-scale production. In recent years, the convergence of nanomedicine and nanocatalysis has highlighted the potential of nanozymes in diagnostic and therapeutic applications, particularly in tumor therapy. Despite these advancements, the clinical translation of nanozymes remains hindered by the lack of designs tailored to specific tumor characteristics, limiting their effectiveness in targeted therapy. This review addresses the mechanisms by which nanozymes induce cell death in various tumor types and emphasizes the key design considerations needed to enhance their therapeutic potential. By identifying the challenges and opportunities in the field, this study aims to provide a foundation for future nanozyme development, ultimately contributing to more precise and effective cancer treatments.
Literature
1.
Islami F, Goding Sauer A, Miller KD, et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J Clin. 2018;68(1):31–54.PubMedCrossRef
2.
Rosic G, Selakovic D, Omarova S. Cancer signaling, cell/gene therapy, diagnosis and role of nanobiomaterials. Adv Biol Earth Sci. 2024;9:11–34.CrossRef
3.
Pei Z, Chen S, Ding L, et al. Current perspectives and trend of nanomedicine in cancer: a review and bibliometric analysis. J Control Release. 2022;352:211–41.PubMedCrossRef
4.
Amirova M. Specific biochemical indicators and inflammatory markers in rheumatoid arthritis (RA). Adv Biol Earth Sci. 2024;9(1):175–83.CrossRef
5.
Miryusifova K, et al. The saffron effects on the dynamics of experimental epilepsy. Adv Biol Earth Sci. 2024;9(1):196–202.CrossRef
6.
Karadağ M, et al. Use of Prunus armeniaca L. seed oil and pulp in health and cosmetic products. Adv Biol Earth Sci. 2024;9(1):105–10.CrossRef
7.
8.
Salahshour P, et al. Nanobiomaterials/bioinks based scaffolds in 3D bioprinting for tissue engineering and artificial human organs. Adv Biol Earth Sci. 2024;9:97–104.CrossRef
9.
10.
Tong X, Tang R, Xiao M, et al. Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research. J Hematol Oncol. 2022;15:174.PubMedPubMedCentralCrossRef
11.
Yao J, Peng H, Qiu Y, et al. Nanoplatform-mediated calcium overload for cancer therapy. J Mater Chem B. 2022;10(10):1508–19.PubMedCrossRef
12.
Li J, Yi X, Liu L, et al. Advances in tumor nanotechnology: theragnostic implications in tumors via targeting regulated cell death. Apoptosis. 2023;28(7–8):1198–215.PubMedCrossRef
13.
Zhang X, Chen X, Zhao Y. Nanozymes: versatile platforms for cancer diagnosis and therapy. Nano Micro Lett. 2022;14(1):95.CrossRef
14.
Gomaa EZ. Nanozymes: a promising horizon for medical and environmental applications. J Cluster Sci. 2022;33(4):1275–97.CrossRef
15.
Ji S, Jiang B, Hao H, et al. Matching the kinetics of natural enzymes with a single-atom iron nanozyme. Nat Catal. 2021;4(5):407–17.CrossRef
16.
Liu C-P, Wu T-H, Liu C-Y, et al. Self-supplying O2 through the catalase-like activity of gold nanoclusters for photodynamic therapy against hypoxic cancer cells. Small. 2017;13(26):1700278.CrossRef
17.
Muhammad P, Hanif S, Li J, et al. Carbon dots supported single Fe atom nanozyme for drug-resistant glioblastoma therapy by activating autophagy-lysosome pathway. Nano Today. 2022;45: 101530.CrossRef
18.
Chen X, Yang Y, Ye G, et al. Chiral ruthenium nanozymes with self-cascade reaction driven the no generation induced macrophage M1 polarization realizing the lung cancer “cocktail therapy.” Small. 2023;19:2207823.CrossRef
19.
Tao N, Li H, Deng L, et al. A cascade nanozyme with amplified sonodynamic therapeutic effects through comodulation of hypoxia and immunosuppression against cancer. ACS Nano. 2022;16(1):485–501.PubMedCrossRef
20.
Jana D, He B, Chen Y, et al. A defect-engineered nanozyme for targeted NIR-II photothermal immunotherapy of cancer. Adv Mater. 2022;36:2206401.CrossRef
21.
Peng F, Liao M, Qin R, et al. Regulated cell death (RCD) in cancer: key pathways and targeted therapies. Signal Transduct Target Ther. 2022;7(1):1–66.
22.
Ketelut-Carneiro N, Fitzgerald KA. Apoptosis, pyroptosis, and necroptosis-oh my! the many ways a cell can die. J Mol Biol. 2022;434(4): 167378.PubMedCrossRef
23.
24.
25.
Li B, Bai Y, Yion C, et al. Single-atom nanocatalytic therapy for suppression of neuroinflammation by inducing autophagy of abnormal mitochondria. ACS Nano. 2023;17(8):7511–29.PubMedCrossRef
26.
Cao F, Sang Y, Liu C, et al. Self-adaptive single-atom catalyst boosting selective ferroptosis in tumor cells. ACS Nano. 2022;16(1):855–68.PubMedCrossRef
27.
Meng X, Li D, Chen L, et al. High-performance self-cascade pyrite nanozymes for apoptosis-ferroptosis synergistic tumor therapy. ACS Nano. 2021;15(3):5735–51.PubMedCrossRef
28.
Xu T, Ma Y, Yuan Q, et al. Enhanced ferroptosis by oxygen-boosted phototherapy based on a 2-in-1 nanoplatform of ferrous hemoglobin for tumor synergistic therapy. ACS Nano. 2020;14(3):3414–25.PubMedCrossRef
29.
Dong C, Dai X, Wang X, et al. A calcium fluoride nanozyme for ultrasound-amplified and Ca2+ -overload-enhanced catalytic tumor nanotherapy. Adv Mater (Deerfield Beach, Fla). 2022;34(43): e2205680.CrossRef
30.
Wang Z, Wang X, Dai X, et al. 2D catalytic nanozyme enables cascade enzyodynamic effect-boosted and Ca2+ overload-induced synergistic ferroptosis/apoptosis in tumor. Adv Mater (Deerfield Beach, Fla). 2024;36: e2312316.CrossRef
31.
Chang M, Zhang L, Zhang T, et al. Ultrasound-augmented enzyodynamic-Ca2+ overload synergetic tumor nanotherapy. Biomaterials. 2024;307: 122513.PubMedCrossRef
32.
Chang M, Wang Z, Dong C, et al. Ultrasound-amplified enzyodynamic tumor therapy by perovskite nanoenzyme-enabled cell pyroptosis and cascade catalysis. Adv Mater. 2022;35:2208817.CrossRef
33.
Tao N, Jiao L, Li H, et al. A mild hyperthermia hollow carbon nanozyme as pyroptosis inducer for boosted antitumor immunity. ACS Nano. 2023;17(22):22844–58.PubMedCrossRef
34.
Yao H, Gong X, Geng M, et al. Cascade nanozymes based on the “butterfly effect” for enhanced starvation therapy through the regulation of autophagy. Biomater Sci. 2022;10(14):4008–22.PubMedCrossRef
35.
Wang Y, Huang Y, Fu Y, et al. Reductive damage induced autophagy inhibition for tumor therapy. Nano Res. 2023;16(4):5226–36.PubMedCrossRef
36.
Yin N, Wang Y, Huang Y, et al. Modulating nanozyme-based nanomachines via microenvironmental feedback for differential photothermal therapy of orthotopic gliomas. Adv Sci. 2023;10(3): e2204937.CrossRef
37.
38.
Shen Z, Song J, Yung BC, et al. Emerging strategies of cancer therapy based on ferroptosis. Adv Mater. 2018;30(12):1704007.CrossRef
39.
Zhou H, Guo M, Li J, et al. Hypoxia-triggered self-assembly of ultrasmall iron oxide nanoparticles to amplify the imaging signal of a tumor. J Am Chem Soc. 2021;143(4):1846–53.PubMedCrossRef
40.
Zheng P, Ding B, Shi R, et al. A multichannel Ca2+ nanomodulator for multilevel mitochondrial destruction-mediated cancer therapy. Adv Mater. 2021;33(15):2007426.CrossRef
41.
Pesakhov S, Nachliely M, Barvish Z, et al. Cancer-selective cytotoxic Ca 2+ overload in acute myeloid leukemia cells and attenuation of disease progression in mice by synergistically acting polyphenols curcumin and carnosic acid. Oncotarget. 2016;7(22):31847–61.PubMedPubMedCentralCrossRef
42.
Shen J, Yu H, Shu Y, et al. A robust ROS generation strategy for enhanced chemodynamic/photodynamic therapy via H2O2/O2 self-supply and Ca2+ overloading. Adv Func Mater. 2021;31(50):2106106.CrossRef
43.
Chu X, Jiang X, Liu Y, et al. Nitric oxide modulating calcium store for ca2+-initiated cancer therapy. Adv Func Mater. 2021;31(13):2008507.CrossRef
44.
Gong F, Xu J, Liu B, et al. Nanoscale CaH2 materials for synergistic hydrogen-immune cancer therapy. Chem. 2022;8(1):268–86.CrossRef
45.
Zhang M, Song R, Liu Y, et al. Calcium-overload-mediated tumor therapy by calcium peroxide nanoparticles. Chem. 2019;5(8):2171–82.CrossRef
46.
Zychlinsky A, Prevost MC, Sansonetti PJ. Shigella flexneri induces apoptosis in infected macrophages. Nature. 1992;358(6382):167–9.PubMedCrossRef
47.
48.
Cookson BT, Brennan MA. Pro-inflammatory programmed cell death. Trends Microbiol. 2001;9(3):113–4.PubMedCrossRef
49.
Zheng P, Ding B, Zhu G, et al. Biodegradable Ca 2+ nanomodulators activate pyroptosis through mitochondrial Ca 2+ overload for cancer immunotherapy. Angew Chem Int Ed. 2022;61(36): e202204904.CrossRef
50.
Rubinsztein DC, Codogno P, Levine B. Autophagy modulation as a potential therapeutic target for diverse diseases. Nat Rev Drug Discov. 2012;11(9):709–30.PubMedPubMedCentralCrossRef
51.
Wang Y, Lin Y-X, Wang J, et al. In situ manipulation of dendritic cells by an autophagy-regulative nanoactivator enables effective cancer immunotherapy. ACS Nano. 2019;13(7):7568–77.PubMedCrossRef
52.
Duo Y, Yang M, Du Z, et al. CX-5461-loaded nucleolus-targeting nanoplatform for cancer therapy through induction of pro-death autophagy. Acta Biomater. 2018;79:317–30.PubMedCrossRef
53.
Wang X, Li M, Ren K, et al. On-demand autophagy cascade amplification nanoparticles precisely enhanced oxaliplatin-induced cancer immunotherapy. Adv Mater. 2020;32(32):2002160.CrossRef
54.
Yin N, Wang Y, Huang Y, et al. Modulating nanozyme-based nanomachines via microenvironmental feedback for differential photothermal therapy of orthotopic gliomas. Adv Sci. 2023;10(3):2204937.CrossRef
55.
Nie D, Ling Y, Lv W, et al. In situ attached photothermal immunomodulation-enhanced nanozyme for the inhibition of postoperative malignant glioma recurrence. ACS Nano. 2023;17(14):13885–902.PubMedCrossRef
56.
Qian X, Shi R, Chen J, et al. The single-atom iron nanozyme mimicking peroxidase remodels energy metabolism and tumor immune landscape for synergistic chemodynamic therapy and photothermal therapy of triple-negative breast cancer. Front Bioeng Biotechnol. 2022;10:1026761.PubMedPubMedCentralCrossRef
57.
58.
Xie Y, Wang M, Qian Y, et al. Novel PdPtCu nanozymes for reprogramming tumor microenvironment to boost immunotherapy through endoplasmic reticulum stress and blocking IDO-mediated immune escape. Small. 2023;19:2303596.CrossRef
59.
Liu J, Wang A, Liu S, et al. A titanium nitride nanozyme for pH-responsive and irradiation-enhanced cascade-catalytic tumor therapy. Angew Chem Int Ed. 2021;60(48):25328–38.CrossRef
60.
Zeng W, Yu M, Chen T, et al. Polypyrrole nanoenzymes as tumor microenvironment modulators to reprogram macrophage and potentiate immunotherapy. Adv Sci. 2022;9(23):2201703.CrossRef
61.
Zhu Y, Wang W, Cheng J, et al. Stimuli-responsive manganese single-atom nanozyme for tumor therapy via integrated cascade reactions. Angew Chem. 2021;133(17):9566–74.CrossRef
62.
Liu Y, Wang B, Zhu J, et al. Single-atom nanozyme with asymmetric electron distribution for tumor catalytic therapy by disrupting tumor redox and energy metabolism homeostasis. Adv Mater. 2023;35:2208512.CrossRef
63.
Cai S, Liu J, Ding J, et al. Tumor-microenvironment-responsive cascade reactions by a cobalt-single-atom nanozyme for synergistic nanocatalytic chemotherapy. Angew Chem Int Ed. 2022;61(48): e202204502.CrossRef
64.
Xu B, Li S, Zheng L, et al. A bioinspired five-coordinated single-atom iron nanozyme for tumor catalytic therapy. Adv Mater. 2022;34(15):2107088.CrossRef
65.
Ye J, Lv W, Li C, et al. Tumor response and NIR-II photonic thermal co-enhanced catalytic therapy based on single-atom manganese nanozyme. Adv Func Mater. 2022;32(47):2206157.CrossRef
66.
Yuan H, Xia P, Sun X, et al. Photothermal nanozymatic nanoparticles induce ferroptosis and apoptosis through tumor microenvironment manipulation for cancer therapy. Small. 2022;18(41):2202161.CrossRef
67.
Zhang C, Chen L, Bai Q, et al. Nonmetal graphdiyne nanozyme-based ferroptosis-apoptosis strategy for colon cancer therapy. ACS Appl Mater Interfaces. 2022;14(24):27720–32.PubMedCrossRef
68.
Wang L, Zhang X, You Z, et al. Charges-enhanced molybdenum disulfide nanozyme activity for ultrasound-mediated cascade-catalytic tumor ferroptosis. Angew Chem Int Ed. 2022;135:202217448.CrossRef
69.
Wei Y, Wu S, Liu Z, et al. Tumor associated macrophages reprogrammed by targeted bifunctional bioorthogonal nanozymes for enhanced tumor immunotherapy. Mater Today. 2022;56:16–28.CrossRef
70.
Zhao J, Duan W, Liu X, et al. Microneedle patch integrated with porous silicon confined dual nanozymes for synergistic and hyperthermia-enhanced nanocatalytic ferroptosis treatment of melanoma. Adv Func Mater. 2023;33(47):2308183.CrossRef
71.
Tang M, Shi Y, Lu L, et al. Dual active nanozyme-loaded MXene enables hyperthermia-enhanced tumor nanocatalytic therapy. Chem Eng J. 2022;449: 137847.CrossRef
72.
Liang Y, Liao C, Guo X, et al. RhRu alloy-anchored mxene nanozyme for synergistic osteosarcoma therapy. Small. 2023;19(22):2205511.CrossRef
73.
Sun Y, Liu X, Wang L, et al. High-performance SOD mimetic enzyme Au@Ce for arresting cell cycle and proliferation of acute myeloid leukemia. Bioact Mater. 2022;10:117–30.PubMed
74.
Kong F, He H, Bai H, et al. A biomimetic nanocomposite with enzyme-like activities and CXCR4 antagonism efficiently enhances the therapeutic efficacy of acute myeloid leukemia. Bioact Mater. 2022;18:526–38.PubMedPubMedCentral
75.
Kong F, Bai H, Ma M, et al. Fe3O4@Pt nanozymes combining with CXCR4 antagonists to synergistically treat acute myeloid leukemia. Nano Today. 2021;37: 101106.CrossRef
76.
77.
Arvanitis CD, Ferraro GB, Jain RK. The blood-brain barrier and blood-tumour barrier in brain tumours and metastases. Nat Rev Cancer. 2020;20(1):26–41.PubMedCrossRef
78.
Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–66.PubMedCrossRef
79.
Zhou Y, Peng Z, Seven ES, et al. Crossing the blood-brain barrier with nanoparticles. J Control Release. 2018;270:290–303.PubMedCrossRef
80.
Li X, Geng X, Chen Z, et al. Recent advances in glioma microenvironment-response nanoplatforms for phototherapy and sonotherapy. Pharmacol Res. 2022;179: 106218.PubMedCrossRef
81.
Lee C, Hwang HS, Lee S, et al. Rabies virus-inspired silica-coated gold nanorods as a photothermal therapeutic platform for treating brain tumors. Adv Mater (Deerfield Beach, Fla). 2017;29(13): e28134459.
82.
Ou M, Cho H-Y, Fu J, et al. Inhibition of autophagy and induction of glioblastoma cell death by NEO214, a perillyl alcohol-rolipram conjugate. Autophagy. 2023;19(12):3169–88.PubMedPubMedCentralCrossRef
83.
Zhan Z, Zeng W, Liu J, et al. Engineered biomimetic copper sulfide nanozyme mediates “don’t eat me” signaling for photothermal and chemodynamic precision therapies of breast cancer. ACS Appl Mater Interfaces. 2023;15(20):24071–83.PubMedCrossRef
84.
Zhou S, Tian T, Meng T, et al. Tumor-derived covalent organic framework nanozymes for targeted chemo-photothermal combination therapy. IScience. 2023;26(8):107348.PubMedPubMedCentralCrossRef
85.
Wang X, Chen Q, Zhu Y, et al. Destroying pathogen-tumor symbionts synergizing with catalytic therapy of colorectal cancer by biomimetic protein-supported single-atom nanozyme. Signal Transduct Target Ther. 2023;8(1):1–12.
86.
87.
Kabel AM. Tumor markers of breast cancer: new prospectives. J Oncol Sci. 2017;3(1):5–11.CrossRef
88.
Mitri Z, Constantine T, O’Regan R. The HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy. Chemother Res Pract. 2012;2012: 743193.PubMedPubMedCentral
89.
Pareja F, Geyer FC, Marchiò C, et al. Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants. Npj Breast Cancer. 2016;2(1):1–11.CrossRef
90.
Wan G, Chen B, Li L, et al. Nanoscaled red blood cells facilitate breast cancer treatment by combining photothermal/photodynamic therapy and chemotherapy. Biomaterials. 2018;155:25–40.PubMedCrossRef
91.
Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938–48.PubMedCrossRef
92.
Zeng X, Ruan Y, Chen Q, et al. Biocatalytic cascade in tumor microenvironment with a Fe2O3/Au hybrid nanozyme for synergistic treatment of triple negative breast cancer. Chem Eng J. 2023;452: 138422.CrossRef
93.
Kadkhoda J, Tarighatnia A, Tohidkia MR, et al. Photothermal therapy-mediated autophagy in breast cancer treatment: progress and trends. Life Sci. 2022;298: 120499.PubMedCrossRef
94.
Gustalik J, Aebisher D, Bartusik-Aebisher D. Photodynamic therapy in breast cancer treatment. J Appl Biomed. 2022;20(3):98–105.PubMedCrossRef
95.
Liu G, Liu M, Li X, et al. Peroxide-simulating and GSH-depleting nanozyme for enhanced chemodynamic/photodynamic therapy via induction of multisource ROS. ACS Appl Mater Interfaces. 2023;15(41):47955–68.PubMedCrossRef
96.
Liu Y, Wang P, Liu Q, et al. Sinoporphyrin sodium triggered sono-photodynamic effects on breast cancer both in vitro and in vivo. Ultrason Sonochem. 2016;31:437–48.PubMedCrossRef
97.
98.
99.
100.
The Lancet Null. Lung cancer: some progress, but still a lot more to do. Lancet (London, England). 2019;394(10212):1880.CrossRef
101.
Chaft JE, Rimner A, Weder W, et al. Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer. Nat Rev Clin Oncol. 2021;18(9):547–57.PubMedPubMedCentralCrossRef
102.
Allison R, Moghissi K, Downie G, et al. Photodynamic therapy (PDT) for lung cancer. Photodiagn Photodyn Ther. 2011;8(3):231–9.CrossRef
103.
104.
Zhou K, Li S, Zhao Y, et al. Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer. Front Immunol. 2023;14:1127071.PubMedPubMedCentralCrossRef
105.
106.
107.
Anwanwan D, Singh SK, Singh S, et al. (2020) Challenges in liver cancer and possible treatment approaches. Biochim Et Biophys Acta. 1873;1:188314.
108.
Li X, Ramadori P, Pfister D, et al. The immunological and metabolic landscape in primary and metastatic liver cancer. Nat Rev Cancer. 2021;21(9):541–57.PubMedCrossRef
109.
110.
Piñero F, Dirchwolf M, Pessôa MG. Biomarkers in hepatocellular carcinoma: diagnosis, prognosis and treatment response assessment. Cells. 2020;9(6):1370.PubMedPubMedCentralCrossRef
111.
Tsukuma H, Tanaka H, Ajiki W, et al. Liver cancer and its prevention. Asian Pac J Cancer Prev APJCP. 2005;6(3):244–50.PubMed
112.
Tang A, Hallouch O, Chernyak V, et al. Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. Abdom Radiol. 2018;43(1):13–25.CrossRef
113.
Zhu K, Dai Z, Zhou J. Biomarkers for hepatocellular carcinoma: progression in early diagnosis, prognosis, and personalized therapy. Biomark Res. 2013;1(1):10.PubMedPubMedCentralCrossRef
114.
Jing H, Ren Y, Zhou Y, et al. Remodeling of the liver fibrosis microenvironment based on nilotinib-loaded multicatalytic nanozymes with boosted antifibrogenic activity. Acta Pharm Sin B. 2023;13(12):5030–47.PubMedPubMedCentralCrossRef
115.
Favoriti P, Carbone G, Greco M, et al. Worldwide burden of colorectal cancer: a review. Updat Surg. 2016;68(1):7–11.CrossRef
116.
Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet (London, England). 2014;383(9927):1490–502.PubMedCrossRef
117.
118.
Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008;454(7203):436–44.PubMedCrossRef
119.
Vong LB, Yoshitomi T, Matsui H, et al. Development of an oral nanotherapeutics using redox nanoparticles for treatment of colitis-associated colon cancer. Biomaterials. 2015;55:54–63.PubMedCrossRef
120.
Miao Z, Jiang S, Ding M, et al. Ultrasmall rhodium nanozyme with RONS scavenging and photothermal activities for anti-inflammation and antitumor theranostics of colon diseases. Nano Lett. 2020;20(5):3079–89.PubMedCrossRef
121.
Huang S, Ding D, Lan T, et al. Multifunctional nanodrug performs sonodynamic therapy and inhibits TGF-β to boost immune response against colorectal cancer and liver metastasis. Acta Biomater. 2023;164:538–52.PubMedCrossRef
122.
Zhang Y, Zhao J, Zhang L, et al. A cascade nanoreactor for enhancing sonodynamic therapy on colorectal cancer via synergistic ROS augment and autophagy blockage. Nano Today. 2023;49: 101798.CrossRef
123.
Wong CC, Yu J. Gut microbiota in colorectal cancer development and therapy. Nat Rev Clin Oncol. 2023;20(7):429–52.PubMedCrossRef
124.
125.
Chen C, Xie L, Ren T, et al. Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs. Cancer Lett. 2021;500:1–10.PubMedCrossRef
126.
Marina NM, Smeland S, Bielack SS, et al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol. 2016;17(10):1396–408.PubMedPubMedCentralCrossRef
127.
Smeland S, Bielack SS, Whelan J, et al. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur J Cancer. 2019;109:36–50.PubMedPubMedCentralCrossRef
128.
Meltzer PS, Helman LJ. New horizons in the treatment of osteosarcoma. N Engl J Med. 2021;385(22):2066–76.PubMedCrossRef
129.
Chen B, Xiang H, Pan S, et al. Advanced theragenerative biomaterials with therapeutic and regeneration multifunctionality. Adv Func Mater. 2020;30(34):2002621.CrossRef
130.
131.
Aglietta M, De Vincentiis A, Lanata L, Lanza F, Lemoli RM, Menichella G, Tafuri A, Zanon P, Tura S. Peripheral blood stem cells in acute myeloid leukemia: biology and clinical applications. Haematologica. 1996;81:77.PubMed
132.
Rautenberg C, Germing U, Haas R, et al. Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: prevention, detection, and treatment. Int J Mol Sci. 2019;20(1):228.PubMedPubMedCentralCrossRef
133.
134.
135.
Zhang H, Fang H, Wang K. Reactive oxygen species in eradicating acute myeloid leukemic stem cells. Stem Cell Investig. 2014;1:13.PubMedPubMedCentral
136.
Metadata
Title
Towards precision medicine: design considerations for nanozymes in tumor treatment
Authors
Xinqiao Li
Jinpeng Hu
Qi Zhao
Weifeng Yao
Zhitao Jing
Zhizhong Jin
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2024
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-024-05845-w

Other articles of this Issue 1/2024

Targeting interleukin-6 as a treatment approach for peritoneal carcinomatosis

Predictive models for personalized precision medical intervention in spontaneous regression stages of cervical precancerous lesions

Ubiquitylation of RUNX3 by RNA-binding ubiquitin ligase MEX3C promotes tumorigenesis in lung adenocarcinoma

Unveiling novel cell clusters and biomarkers in glioblastoma and its peritumoral microenvironment at the single-cell perspective

Gastroesophageal reflux disease and the risk of respiratory diseases: a Mendelian randomization study

Analysis of differences in intestinal flora associated with different BMI status in colorectal cancer patients

Keynote webinar | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the broader systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now

Keynote webinar | Spotlight on adolescent vaping

  • Live
  • Webinar | 29-01-2025 | 18:00 (CET)

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Watch it live: Wednesday 29th January, 18:00-19:30 CET
 

Prof. Ann McNeill
Dr. Debbie Robson
Benji Horwell
Developed by: Springer Medicine
Join the webinar

Keynote webinar | Spotlight on modern management of frailty

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft
Prof. Barbara C. van Munster
Prof. Mirko Petrovic
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more
Image Credits